Application of physiologically-based pharmacokinetic modeling in hepatic impairment populations

被引：0
|
作者：
Sager, Jennifer [3 ]
Hsu, Matt [2 ]
Isoherranen, Nina [3 ]
Wienkers, Larry [1 ]
Wahlstrom, Jan [1 ]
Foti, Robert [1 ]
机构：
[1] Amgen Inc, Pharmacokinet & Drug Metab, Seattle, WA USA
[2] Amgen Inc, Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA
[3] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA
来源：
FASEB JOURNAL | 2014年 / 28卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
1064.9
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective
    Heimbach, Tycho
    Chen, Yuan
    Chen, Jun
    Dixit, Vaishali
    Parrott, Neil
    Peters, Sheila Annie
    Poggesi, Italo
    Sharma, Pradeep
    Snoeys, Jan
    Shebley, Mohamad
    Tai, Guoying
    Tse, Susanna
    Upreti, Vijay V.
    Wang, Ying-Hong
    Tsai, Alice
    Xia, Binfeng
    Zheng, Ming
    Zhu, Andy Z. X.
    Hall, Stephen
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (02) : 297 - 310
  • [2] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF ESOMEPRAZOLE IN THE HEPATIC IMPAIRMENT POPULATION
    Hoang, T.
    Arya, V.
    Zhang, X.
    Ayyoub, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S5 - S5
  • [3] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF ESOMEPRAZOLE IN THE HEPATIC IMPAIRMENT POPULATION.
    Hoang, T.
    Arya, V.
    Zhang, X.
    Ayyoub, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S86 - S86
  • [4] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF ESOMEPRAZOLE IN THE HEPATIC IMPAIRMENT POPULATION.
    Hoang, T.
    Arya, V.
    Zhang, X.
    Ayyoub, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S79 - S79
  • [5] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING FOR PREGNANCY
    Liu, X.
    Leong, R.
    Buckart, G.
    Dallmann, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S117 - S117
  • [6] Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations
    Xu, Yichao
    Zhang, Lei
    Dou, Xiaofan
    Dong, Yongze
    Guo, Xiangchai
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (02) : 261 - 271
  • [7] Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations
    Yichao Xu
    Lei Zhang
    Xiaofan Dou
    Yongze Dong
    Xiangchai Guo
    [J]. European Journal of Clinical Pharmacology, 2024, 80 : 261 - 271
  • [8] Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
    Shen, Chaozhuang
    Shao, Wenxin
    Wang, Wenhui
    Sun, Hua
    Wang, Xiaohu
    Geng, Kuo
    Wang, Xingwen
    Xie, Haitang
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (07): : 1001 - 1015
  • [9] Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations
    Guo, Lingfeng
    Zhu, Xinyu
    Zhang, Lei
    Xu, Yichao
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2023, 14
  • [10] Pharmacokinetics and Physiologically-Based Pharmacokinetic Modeling of Nanoparticles
    Yang, Raymond S. H.
    Chang, Louis W.
    Yang, Chung Shi
    Lin, Pinpin
    [J]. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2010, 10 (12) : 8482 - 8490
12345